Product Description
Amrubicin is a synthetic 9-amino-anthracycline with antineoplastic activity. Amrubicin intercalates into DNA and inhibits the activity of topoisomerase II, resulting in inhibition of DNA replication, and RNA and protein synthesis, followed by cell growth inhibition and cell death. This agent has demonstrated a higher level of anti-tumor activity than conventional anthracycline drugs without exhibiting any indication of the cumulative cardiac toxicity common to this class of compounds. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Amrubicin)
Mechanisms of Action: TOP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Small Cell Lung Cancer|Lung Cancer
Phase 2: Small Cell Lung Cancer|Thymoma|Thymus Cancer|Breast Cancer|Multiple Myeloma|Sarcoma|Bladder Cancer|Transitional Cell Carcinoma
Phase 1: Lung Cancer|Heart Cancer|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IRB-19092 | P2 |
Completed |
Multiple Myeloma |
2016-07-01 |
|
| ARSARC-PI-0010 | P2 |
Completed |
Sarcoma |
2016-02-01 |
|
| IRB-20444 | P2 |
Completed |
Thymus Cancer|Thymoma |
2014-07-01 |
|
| GCO 10-1341 | P2 |
Terminated |
Transitional Cell Carcinoma|Bladder Cancer |
2014-07-01 |